elranatamab   Click here for help

GtoPdb Ligand ID: 12889

Synonyms: elranatamab-bcmm | Elrexfio® | PF-06863135 | PF06863135
Approved drug Immunopharmacology Ligand
elranatamab is an approved drug (FDA & EMA (2023))
Compound class: Antibody
Comment: Elranatamab (PF-06863135) is a TNFRSF17(BCMA)/CD3e bispecific monoclonal antibody. It was designed to promote T cell-mediated anti-myeloma activity by simultaneously engaging these two protein targets on B and T cells [1,3].
No information available.
Summary of Clinical Use Click here for help
The FDA approved elranatamab in August 2023, to treat relapsed or refractory multiple myeloma (RRMM). It is administered subcutaneously.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03269136 PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma Phase 1 Interventional Pfizer
NCT05020236 MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Phase 3 Interventional Pfizer
NCT04649359 MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb Phase 2 Interventional Pfizer 2